Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 11:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Pulmonary Disease COPD Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

NCT01323634
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 16, 2026, 11:35 PM EDT
Completed Phase 4 Interventional Results available

Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01543828
View directory record Official record
Conditions
COPD
Interventions
indacaterol, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
6
States / cities
Fullerton, California • Saint Charles, Missouri • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 16, 2026, 11:35 PM EDT
Terminated Not applicable Interventional

Impact of Non-invasive Ventilation in Hypercapnic COPD

NCT03522805
View directory record Official record
Conditions
Copd, Chronic Obstructive Pulmonary Disease, Hypercapnia, Chronic Respiratory Failure, Hypoventilation
Interventions
High-intensity non-invasive ventilation
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
45 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 16, 2026, 11:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adverse Health Effects of Mainstream and Secondhand Hookah Smoke in NYC Hookah Bars

NCT02638194
View directory record Official record
Conditions
COPD
Interventions
Active smoking of Tobacco Hookah for 2 hours, Exposure to tobacco hookah second hand smoke, Visit a win bar
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 16, 2026, 11:35 PM EDT
Completed Phase 1Phase 2 Interventional

Dyspnea Self-Management: Internet or Face-to-Face

NCT00461162
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Internet DSMP, Face-to-Face Dyspnea Self-management, Attention Control
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 16, 2026, 11:35 PM EDT
Terminated No phase listed Observational

Assessment of Utility of accelerateIQ in the Care of Patients Participating in a Pulmonary Rehabilitation Program

NCT03879291
View directory record Official record
Conditions
COPD, Pulmonary Rehabilitation
Interventions
pinpointIQ
Other
Lead sponsor
Karen Larimer
Industry
Eligibility
40 Years and older
Enrollment
5 participants
Timeline
2019
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 16, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

Tezepelumab COPD Exacerbation Study

NCT04039113
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
27
States / cities
Dothan, Alabama • Huntington Beach, California • Newport Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 16, 2026, 11:35 PM EDT
Completed Phase 2 Interventional

Dose Finding Study of CHF 4226 for Treating Patients With COPD

NCT00605891
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
carmoterol (CHF 4226), salmeterol, placebo
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years to 75 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
24
States / cities
Jonesboro, Arkansas • Fresno, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 16, 2026, 11:35 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD

NCT03674320
View directory record Official record
Conditions
COPD
Interventions
Testosterone Enanthate, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 16, 2026, 11:35 PM EDT
Completed Phase 4 Interventional Results available

Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

NCT00181207
View directory record Official record
Conditions
COPD, Chronic Bronchitis, Emphysema
Interventions
pneumatic vest, placebo pneumatic vest
Device · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 16, 2026, 11:35 PM EDT
Completed Phase 4 Interventional Results available

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1

NCT01663987
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
49
States / cities
Birmingham, Alabama • Florence, Alabama • Fountain Valley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 16, 2026, 11:35 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00782535
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
CHF 4226 pMDI, Placebo
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
DeLand, Florida • Madisonville, Kentucky • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 16, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

NCT04631016
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis
Interventions
Tozorakimab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Sheffield, Alabama • Newport Beach, California • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 16, 2026, 11:35 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

NCT06981078
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Verekitug, Placebo
Drug · Other
Lead sponsor
Upstream Bio Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
29
States / cities
Bakersfield, California • Encino, California • Lomita, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 16, 2026, 11:35 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT02536508
View directory record Official record
Conditions
COPD
Interventions
BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BFF MDI 320/9.6 μg
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
64
States / cities
Dothan, Alabama • Jasper, Alabama • Peoria, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 16, 2026, 11:35 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD

NCT00239447
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, HandiHaler, Respimat SMI
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
10
States / cities
Little Rock, Arkansas • San Diego, California • San Jose, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 16, 2026, 11:35 PM EDT
Completed Not applicable Interventional

Fish Oil and HMB Supplementation in COPD

NCT03796455
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Capsule + Powder supplementation, stable tracer infusion
Dietary Supplement · Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 100 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 16, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.

NCT03281876
View directory record Official record
Conditions
Respiratory Disorders
Interventions
NTHi Mcat investigational vaccine (GSK3277511A), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
25
States / cities
Mesa, Arizona • Phoenix, Arizona • Palm Springs, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 16, 2026, 11:35 PM EDT
Completed Phase 3 Interventional

A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD

NCT00308191
View directory record Official record
Conditions
COPD
Interventions
Formoterol Fumarate, Tiotropium Bromide
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Sepulveda, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2008 · Synced Oct 16, 2026, 11:35 PM EDT
Withdrawn Not applicable Interventional

A Novel Unidirectional Face Mask During NPPV in COPD Patients

NCT00972868
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
A unidirectional face mask (Modified 'Respironics PerformaTrak' Mask)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 16, 2026, 11:35 PM EDT
Completed No phase listed Observational

Medication Adherence Research in COPD Patients

NCT03174704
View directory record Official record
Conditions
COPD, Medication Adherence
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Newark, Delaware • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 16, 2026, 11:35 PM EDT
Completed No phase listed Observational

Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease

NCT02055222
View directory record Official record
Conditions
Pulmonary Fibrosis, Lung Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 16, 2026, 11:35 PM EDT
Completed No phase listed Observational

Use of Respiratory Therapists (RTs) to Improve Outcomes and Quality of Life in Patients With COPD

NCT02078622
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Respiratory Therapist Education and Case Management
Other
Lead sponsor
StratiHealth
Industry
Eligibility
55 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 16, 2026, 11:35 PM EDT
Recruiting Not applicable Interventional

Evaluation of the Paramedic Evaluation for Acute COPD Exacerbation

NCT07072039
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
Paramedic Evaluation for acute COPD Exacerbation, Usual Care
Procedure
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 11:35 PM EDT